πŸ‡ΊπŸ‡Έ FDA
Patent

US 11548888

KRas G12C inhibitors

granted A61PA61P35/00

Quick answer

US patent 11548888 (KRas G12C inhibitors) held by Mirati Therapeutics, Inc. expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Mirati Therapeutics, Inc.
Grant date
Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61P, A61P35/00